Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma, Mucinous
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Cystadenocarcinoma, Serous
  • Endometrial Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • Abagovomab administered as repeated monthly injections is safe and induces a measurable immune response. Administration as maintenance therapy for patients with ovarian cancer in first remission does not prolong RFS or OS.

authors

publication date

  • April 20, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.46.4057

PubMed ID

  • 23478059

Additional Document Info

start page

  • 1554

end page

  • 61

volume

  • 31

number

  • 12